The development of resistance to cancer therapy is one of the most frequent reasons for the failure of anti-cancer treatments. Therapy resistance is linked to tumor-recurrence and has devastating consequences for the clinical outcome of the individual patient and causes increased costs for public health systems. The understanding of mechanisms of resistance-formation and the development of strategies directed towards the re-sensitization of resistant tumor cells to cancer therapy represents one of the most important challenges to modern cancer research. P-CARE will strengthen the collaboration between Italian and Austrian research institutes in the areas of genetics, biotechnology and the cancer clinics and generate a technical platform to investigate mechanism of therapy resistance formation, aiming to increase the efficacy of therapeutic treatments. The project will develop a shared platform for the identification of drugs capable to re-sensitize resistant tumors to conventional oncologic treatments by the repositioning of drugs already approved for the treatment of other pathologies. Further, P-CARE will implement strategies of precision medicine aiming to overcome resistance to anti-cancer immunotherapy by reproducing the immune response of the tumor-microenvironment in vitro. P-CARE will build an efficient trans-border network for sharing technology and knowledge that will be made accessible for academic and clinical cancer research in and outside the program area.

For further inform see www.p-care.eu

P-Care is a project funded by the European Union, European Regional Development Fund and Interreg V-A Italia-Austria 2014-2020 . The consortium consists of ADSI (Austrian Drug Screening Institute), MUI (Medical University of Innsbruck), SABES (Medical Supplies Enterprise of South Tyrol), UNITS (University of Triest).

Upcoming Biocenter Seminars

Upcoming Life Sciences Seminar